Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Advertisement
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Cipla Cuts Down In-House Biosimilars Plans

Cipla is recalibrating investments in the “resource-intensive” biosimilars business, reinforcing its thrust on the respiratory and specialty products segment. Large biosimilar manufacturing plans in South Africa have been put on hold, with curtains seemingly coming down at an Indian unit.

Commercial Strategy

India’s Simmering Device-Pricing Controversy – Many Hues

An uneasy calm prevails in the medical devices sector in India following regulatory action to cap stent prices and, more recently, a price data-gathering initiative for certain other products. Is this just the lull before another, more turbulent storm that lies ahead for industry?

India Pricing Strategies

US Price Pressure Clouds Lupin Outlook – Can Its Pipeline Deliver?

Lupin reported a sharp decline in its fourth quarter profits, dented by heightened price pressure and competition in the US for its key products. The management sees a ‘challenging’ 2018, but underscored the strength of the firm’s ANDA pipeline and enhanced investments in the biosimilars, inhalation and injectables space.

Commercial Strategy

Come Flood Or High Water – How BioNet Is Shaping Its Vaccine Ambitions

Emerging Company Profile: Thailand-based BioNet stuck it out despite widespread flooding at its site and now expects to take its pertussis vaccine to key Western markets.

StartUps and SMEs Vaccines

Tweaked ‘New Drugs’ Flouted Price Approval Norms In India

Pharmaceutical firms face more flak in India for allegedly flouting pricing norms – this time more than 200 formulations were allegedly launched in the country without seeking price approvals, though some companies claim they are fully compliant with the norms.

Regulation India

Dr Reddy’s Gears Biologics Expansion With GE Platform

Dr Reddy’s Laboratories hopes GE Healthcare’s FlexFactory biomanufacturing platform can deliver multiple operational gains, including a potentially more fail-safe compliance system at its site. The Indian company expects to roll out its first biosimilar MAb from the new set-up next year.

Commercial Companies
See All
Advertisement
UsernamePublicRestriction

Register